Ask about this productRelated genes to: FGF19 antibody
- Gene:
- FGF19 NIH gene
- Name:
- fibroblast growth factor 19
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-06
- Date modifiied:
- 2016-10-05
Related products to: FGF19 antibody
Related articles to: FGF19 antibody
- The cardio-renal-hepatic-metabolic (CRHM) axis represents the bidirectional network through which cardiovascular disease, chronic kidney disease, metabolic dysfunction, and liver disorders propagate injury across organs. Within this network, Klotho has emerged as a context-dependent regulator linking mineral metabolism, metabolic homeostasis, cellular stress, inflammation, and tissue remodelling. Klotho comprises distinct signalling axes: the renal α-Klotho-Fibroblast growth factor (FGF)-23 axis, which governs mineral metabolism, and the hepatic β-Klotho-FGF19/FGF21 axis, regulating energy homeostasis. Declining Klotho availability, particularly with ageing and chronic disease, is associated with excess FGF23, disordered phosphate and vitamin D metabolism, oxidative stress, inflammation, and fibrotic remodelling. Collectively, these contribute to cardiac hypertrophy, vascular calcification, hepatic steatosis, insulin resistance, and progressive renal dysfunction. Importantly, Klotho biology is influenced by tissue context, isoform, disease stage, age and sex. However, human evidence remains largely associative and is derived predominantly from observational studies, and meta-analyses have not established causality. As a biomarker, circulating Klotho faces challenges of assay variability, isoform complexity, and age- and sex-dependent interpretation. Therapeutic strategies, established pharmacological interventions, exercise, recombinant Klotho, Klotho-derived peptides, and gene-based approaches have shown encouraging preclinical and biomarker studies. Still, clinical translation awaits standardized assays, longitudinal cohorts, and mechanism-based randomized trials. Klotho should therefore be viewed as a dynamic marker and modulator of CRHM network integrity, whose significance depends on tissue context, isoform, and disease stage. - Source: PubMed
Publication date: 2026/10/07
Taigade SanikaParab Siddhi BagweDoshi Gaurav - We tested the primary hypothesis that lower continuous 24-hour urinary 6-sulfatoxymelatonin (6-SMT) is associated with an adverse lipid and inflammatory profile in adults with dyslipidemia. Associations with FGF19, bile-acid composition, and gut microbiome features were secondary and exploratory. - Source: PubMed
Publication date: 2026/10/07
Tavartkiladze AlexandreTavartkiladze LevanReiter Russel JBurnier MichelUlukaya EnginSimonia GaianeKasradze DinaraNozadze PirdaraRevazishvili PatiAndronikashvili IrineMaisuradze Maia - The complex cytokine network in seminal fluid during human immunodeficiency virus (HIV) infection remains incompletely understood. This study aimed to investigate inflammatory cytokine levels in the semen of individuals with chronic HIV infection and assess the effects of antiretroviral therapy ART on cytokine networks. - Source: PubMed
Publication date: 2026/10/01
Gao DongmeiMijiti ZilaiguliZhu NingningXu YapingGao Lin - Glycolipid Metabolic Disorders (GLMD) are characterized by imbalances in glucose and lipid homeostasis, often presenting with severe clinical symptoms. Current pharmacotherapies such as orlistat and metformin show clear efficacy but are associated with long-term tolerability concerns. This study aimed to evaluate whether the next-generation probiotic candidate YGMCC0564 attenuates HFD-induced glycolipid metabolic disturbances in mice. We hypothesized that the protective effect of YGMCC0564 would be associated with modulation of bile acid metabolism and may be partly mediated by it. - Source: PubMed
Publication date: 2026/09/21
He ZhiliChen PingZhao MinleiSong WenfangZhang ShichangLei QiuxiangJie XiaochiChen Jianguo - Bile acids (BAs), cholesterol-derived amphipathic metabolites which are traditionally regarded as digestive surfactants, are now recognized as pleiotropic signaling molecules that act through ligand-, receptor-, and tissue-specific mechanisms to maintain systemic homeostasis. They exert biological functions via nuclear receptors (FXR, PXR, VDR, CAR) and membrane receptors (TGR5, S1PR2, MRGPRX4). These receptors activate transcriptional and membrane-initiated programs, including FXR-SHP/FGF19 feedback, TGR5-cAMP-PKA signaling, S1PR2-ERK/AKT/RhoA pathways, MRGPRX4-dependent Ca⁺ signaling, PXR/CAR/VDR-driven detoxification responses, and non-receptor-mediated membrane and mitochondrial stress pathways. This review discusses how the diversity of BA structures, hepatic synthesis, conjugation, transportation, enterohepatic circulation, and microbiota-mediated transformation generates receptor- and tissue-specific signals. Furthermore, we summarize the physiological functions of BA signaling in lipid, glucose, and energy metabolism, intestinal epithelial integrity, mucosal immunity, neuroendocrine regulation, musculoskeletal adaptation, and renal water-salt balance. Additionally, we discuss the effects of disrupted BA signaling on cholestatic and metabolic liver diseases, alcohol-associated liver disease, hepatocellular carcinoma, inflammatory bowel disease, BA diarrhea, colorectal cancer, obesity, type 2 diabetes, atherosclerosis, and biliary tract diseases. Finally, the therapeutic strategies that modulate BA signaling, including the use of FXR and TGR5 agonists, FGF19 analogues, transporter inhibitors, enzyme-targeting methods, microbiota-based treatments, and hydrophilic BA therapies, are evaluated. By categorizing BA biology according to the production of ligands, receptor activation, tissue responses, and disease mechanisms, this review highlights BA signaling as an integrated regulatory network and a tractable therapeutic axis in health and disease. - Source: PubMed
Publication date: 2026/10/02
Fan ZhezheHe MengyiLiang TaipingZhang BiliZhao NaLi Pan